| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| dsp-2230 | voltage-gated sodium channel alpha nav1.8 | NA | Successful target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.84 | phase 1 | blocker |
| dsp-2230 | voltage-gated sodium channel alpha nav1.8 | NA | Successful target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.84 | phase 1 | unknown |
| dsp-2230 | voltage-gated sodium channel alpha nav1.7 | NA | Clinical trial target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.94 | phase 1 | blocker |
| dsp-2230 | voltage-gated sodium channel alpha nav1.7 | NA | Clinical trial target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.94 | phase 1 | unknown |
| click here to return to the previous page | ||||||||